Neomed Institute

Revagenix, Inc.

Epigenetix, Inc.

Malken Bayrakdarian

Andrew Griffin

Stephen Claridge

Shawn Donald Johnstone

Jeffrey S Albert

Guillaume Jacquemot

Mehrnaz Pourashraf

Michael J Lopez

Timothy Robert Kane

Nikolai Evdokimov

Frederick Cohen

Andrew Calabrese

Darin Hildebrandt

Samuel Desjardins

Olivier Soueidan

Marc-Andre Beaulieu

Sanjia Xu

Sanijia Xu

Shawn Johnstone

The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.

Modular synthesis of aminoglycosides

This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Substituted benzimidazoles, their preparation and their use as pharmaceuticals

This application relates to N-substituted bicyclic lactams of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to the N-substituted bicyclic lactams of formula (I) and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. 

N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals

This application relates to substituted [1,2,4]triazolo[4,3-a]pyridines of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted [1,2,4]triazolo[4,3-a]pyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. 

Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals

This application relates to aryl-substituted dihydroquinolinones of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to aryl-substituted dihydroquinolinones and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers. 

Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals

This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines of Formula I and to their use as bromodomain inhibitors.  The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors

Growing community of inventors

Montreal, Canada

Malken Bayrakdarian